This CME program will highlight the safety and efficacy of IL-17 inhibitors in dermatology disease, including information presented at the European Academy of Dermatology and Venereology 34th Annual Congress. The expert faculty, Drs. Steven Feldman, Mark Lebwohl, and Bruce Strober will first review the mechanism of action of IL-17 inhibitors and the biologic rationale for their use. Following, the faculty will delve into approved indications and patient selection considerations for the use of IL-17 inhibitors in dermatologic disease. Lastly, Drs. Feldman, Lebwohl and Strober will discuss new information presented at EADV 2025, including long-term monitoring of specific adverse effects attributed to IL-17 blockers.
Review the MOA of IL-17 inhibitors and the biologic rationale for their use
Discuss the approved indications, use cases, and patient selection considerations for the use of IL-17 inhibitors in dermatologic disease
Review and contextualize new information from EADV 2025 on the long-term monitoring of specific adverse effects attributed to IL-17 blockers
I. Molecular Basis of IL-17 Inhibition in Inflammatory Disease (include IL-17 subtypes) – Steven Feldman, MD, PhD
II. IL-17 Inhibitors in Dermatologic Disease: Indications, Patient Selection – Steven Feldman, MD, PhD
III. Potential Adverse Effects of IL-17 Blockade – Mark Lebwohl, MD
IV. EADV 2025: Update on Long-Term Monitoring and Outcomes of IL-17 Inhibitor Use – Bruce Strober, MD, PhD
It is the policy of AcademicCME that all faculty, instructors, and planners disclose relevant financial relationships with ineligible companies. Planners have no relevant financial relationships with ineligible companies to disclose related to this activity. Faculty have disclosed the following relevant financial relationships. All relevant financial relationships have been mitigated.
| Faculty | Relationship Identified With: |
| Steven Feldman, MD, PhD | Consultant/Advisor: AbbVie; Accordant Company, LLC; Almirall, LLC; Alumis Inc.; Alvotech; Arcutis Biotherapeutics, Inc.; Arena Pharmaceuticals; argenx; Biocon; Boehringer Ingelheim; Bristol-Myers Squibb Company; Dermavant; Forte Biosciences, Inc.; Helsinn; Incyte; Janssen; LEO Pharma; Lilly USA, LLC; Micreos; Mylan; Novartis Pharmaceuticals Corporation; Ono Pharmaceutical CO., LTD.; Ortho Dermatology; Pfizer Inc.; Samsung Biologics; Sanofi; Sun Pharma; UCB; Verrica Pharmaceuticals; Voluntis; vTv Therapeutics Grant/Research Support: AbbVie; Almirall, LLC; Bristol-Myers Squibb Company; Galderma; Incyte; Janssen; LEO Pharma; Lilly USA, LLC; Novartis Pharmaceuticals Corporation; Ortho Dermatology; Perfect Corp; Pfizer Inc.; Target-Derm; UCB Speaker: AbbVie; Alvotech; Amgen Inc.; Boehringer Ingelheim; Bristol-Myers Squibb Company; Janssen; LEO Pharma; Lilly USA, LLC; Ortho Dermatology; Regeneron Pharmaceuticals Inc.; Sanofi; Sun Pharma |
| Mark Lebwohl, MD | Consultant/Advisor: Aikium Inc.; Almirall, LLC; AltruBio Inc., Amgen Inc.; Apogee Therapeutics; Arcutis Biotherapeutics, Inc.; AstraZeneca; Atomwise; Avotres Inc.; Boehringer Ingelheim; Bristol-Myers Squibb Company; Castle Biosciences, Inc.; Celltrion Inc.; CorEvitas, LLC.; Dermavant Sciences, Inc.; Dermsquared; Evommune, Inc., Facilitation of International Dermatology Education; Forte Biosciences, Inc.; Galderma; Genentech, Inc.; Goodrx-Mayne; Incyte; LEO Pharma; Meiji Seika Pharma; Mindera, Mirum Pharmaceuticals; Oruka Therapeutics; Pfizer Inc.; Revolo Biotherapeutics; Sanofi-Regeneron; Seanergy; Stratapharma; Sun Pharma; Takeda Pharmaceutical Company; Trevi Therapeutics; Verrica Pharmaceuticals Grant/Research Support: AbbVie, Arcutis Biotherapeutics, Inc.;Avotres Inc.; Boehringer Ingelheim; Cara Therapeutics, Inc.; Clexio Biosciences; Dermavant Sciences, Inc.; Lilly USA, LLC; Incyte; Inozyme Pharma; Johnson & Johnson; Pfizer Inc.; Sanofi-Regeneron; UCB |
| Bruce Strober, MD, PhD | Consultant/Advisor: AbbVie, Alumis Inc.; Almirall, LLC; Amgen Inc.; Apogee Therapeutics; Arcutis Biotherapeutics, Inc.; Boehringer Ingelheim; Bristol-Myers Squibb Company; CorEvitas, LLC.; Dermavant Sciences, Inc.; Immunovant, Inc.; Janssen; LEO Pharma; Lilly USA, LLC; Maruho Co., Ltd.; Neurocrine Biosciences, Inc.; Novartis Pharmaceuticals Corporation; Oruka Therapeutics; Meiji Seika Pharma; Protagonist Therapeutics Inc.; Pfizer Inc.; UCB; RAPT Therapeutics, Inc.; Regeneron Pharmaceuticals Inc.; Sanofi-Genzyme; selectION, Inc.; Takeda Pharmaceutical Company Speaker: AbbVie, Arcutis Biotherapeutics, Inc.; Lilly USA, LLC; Incyte, Johnson & Johnson; Regeneron Pharmaceuticals Inc.; Sanofi-Genzyme Stock Options: Mindera Health, selectION, Inc. Investigator: CorEvitas Psoriasis and GPP Registries; Oruka Therapeutics; Takeda Pharmaceutical Company; Incyte |
Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC, Chelsey Simonds and Nicole McMenamin hereby state that they or their spouse/life partner do not have any relevant financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
AcademicCME designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditsTM.
AcademicCME designates this enduring material for a maximum of 0.75 CNE Contact Hours, including 0.75 Pharmacotherapeutic Contact Hours (Provider #P0491).
Clinicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been supported by an independent educational grant from UCB.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and UCB do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
In order to claim credit, participants must complete the following:
For all CE inquiries or special needs, please contact admin@academiccme.com.
811 S. Orleans Ave. Tampa, Fl 33606
